RxDoctor Payments Data

Bruce Hayse, MD

General Practice · Jackson, WYNPI 1154491579

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $259 of the $294 with a category attached, or 88.1%. 8 manufacturers reported payments, led by Amgen at 30.1% of the total.

$294in general payments, 2019–2025

Across 14 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$89
  • Novartis$48
  • AstraZeneca$47
  • Pfizer$35
  • Boehringer Ingelheim$24
  • Corium, LLC$19
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$25988%
  • Education$3512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$294 in reported general payments places this provider in the 60th percentile of 145 general practice providers in Wyoming.

See all general practice providers in Wyoming

Medicare billing

Part B allowed, 2024
$133,182
Medicare patients
397
Services billed
1,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$120,802
MounjaroTirzepatide48$58,379
EliquisApixaban71$57,824
Repatha SureclickEvolocumab28$27,758
XareltoRivaroxaban21$18,924
FarxigaDapagliflozin Propanediol12$14,713
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,098
JardianceEmpagliflozin11$6,053
Breo ElliptaFluticasone/Vilanterol12$4,516
Sirolimus14$4,229
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df16$3,974
Atorvastatin Calcium297$3,476
Ventolin HfaAlbuterol Sulfate34$2,172
BelsomraSuvorexant13$1,990
Lisinopril211$1,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$57,82471 claims
AstraZenecaFarxiga, Breztri Aerosphere$47$21,81024 claims
Boehringer IngelheimJardiance$24$6,05311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 145 general practice providers in Wyoming.

Other general practice in Jackson

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →